Fig. 4.
Construction and identification of neoadjuvant immunotherapy mouse models. a The H1299-Luc cell line with high metastatic properties was obtained by serial screening between mouse subcutaneous and liver and lung metastases, and specific screening process is shown in Figure. b The scratch assay was performed to further determine the high metastatic properties of the obtained H1299M-luc. Specifically, the width of scratched areas were measured after 0, 12 and 24 h of scratch, to analyze the migration ability of H1299M-luc cells. c An in vivo imaging system was used to observe the metastatic ability of the H1299M-luc cell line and its paternal line after complete subcutaneous tumor resection, a process that simulates recurrence and metastasis after clinical surgical resection. d When tumors reached a certain volume, mice were treated with bevacizumab combined with pembrolizumab in neoadjuvant setting for 5 days, followed by absolute subcutaneous tumor resection. The specific experimental process is shown in Figure. e The surgically removed subcutaneous tumor was collected and photographed